Organovo Holdings ( (ONVO) ) has issued an announcement.
Organovo Holdings, Inc. announced on April 2, 2025, that it expects to meet the Nasdaq Capital Market’s continued listing requirements, following a period where its stock traded above the $1.00 minimum bid price since March 21, 2025. The company also reported preliminary cash and cash equivalents of approximately $11.3 million as of March 31, 2025, and anticipates a $5 million milestone payment within the next 12 months related to its FXR agonist program, which was recently sold to Eli Lilly and Company.
More about Organovo Holdings
Organovo Holdings, Inc. is a clinical stage biotechnology company focused on developing novel treatment approaches for inflammatory bowel disease (IBD). The company utilizes proprietary technology to create three-dimensional (3D) human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.
YTD Price Performance: -59.60%
Average Trading Volume: 674,093
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3.81M
For a thorough assessment of ONVO stock, go to TipRanks’ Stock Analysis page.